<table border="1" id="table_8" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 8. Drug Interactions - Pharmacokinetic Parameters for Co-administered Drug in the Presence of NORVIR</caption>
<col span="1" width="1778*"></col>
<col span="1" width="1644*"></col>
<col span="1" width="1707*"></col>
<col span="1" width="650*"></col>
<col span="1" width="1467*"></col>
<col span="1" width="1596*"></col>
<col span="1" width="14%"></col>
<tbody>
<tr>
<td>
<content stylecode="bold">Co-administered Drug</content>
</td>
<td>
<content stylecode="bold">Dose of Co-administered Drug (mg)</content>
</td>
<td>
<content stylecode="bold">Dose of NORVIR (mg)</content>
</td>
<td>
<content stylecode="bold">N</content>
</td>
<td>
<content stylecode="bold">AUC % (95% CI)</content>
</td>
<td>
<content stylecode="bold">C<sub>max</sub> (95% CI)</content>
</td>
<td>
<content stylecode="bold">C<sub>min</sub> (95% CI)</content>
</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>1, single dose</td>
<td>500 q12h, 10 d</td>
<td>12</td>
<td>↓ 12% (-5, 30%)</td>
<td>↓ 16% (5, 27%)</td>
<td>ND</td>
</tr>
<tr>
<td>Avanafil</td>
<td>50, single dose</td>
<td>600 q12h</td>
<td>14<sup>6</sup>
</td>
<td>↑ 13-fold</td>
<td>↑ 2.4-fold</td>
<td>ND</td>
</tr>
<tr>
<td>Clarithromycin<br/>
<br/>14-OH clarithromycin metabolite</td>
<td>500 q12h, 4 d</td>
<td>200 q8h, 4 d</td>
<td>22</td>
<td>↑ 77% (56, 103%)<br/>
<br/>↓ 100%</td>
<td>↑ 31% (15, 51%)<br/>
<br/>↓ 99%</td>
<td>↑ 2.8-fold (2.4, 3.3X)<br/>
<br/>↓ 100%</td>
</tr>
<tr>
<td>Desipramine<br/>
<br/>2-OH desipramine metabolite</td>
<td>100, single dose</td>
<td>500 q12h, 12 d</td>
<td>14</td>
<td>↑ 145% (103, 211%)<br/>
<br/>↓ 15% (3, 26%)</td>
<td>↑ 22% (12, 35%)<br/>
<br/>↓ 67% (62, 72%)</td>
<td>ND<br/>
<br/>ND</td>
</tr>
<tr>
<td>Didanosine</td>
<td>200 q12h, 4 d</td>
<td>600 q12h, 4 d</td>
<td>12</td>
<td>↓ 13% (0, 23%)</td>
<td>↓ 16% (5, 26%)</td>
<td>↔</td>
</tr>
<tr>
<td>Ethinyl estradiol</td>
<td>50 µg single dose</td>
<td>500 q12h, 16 d</td>
<td>23</td>
<td>↓ 40% (31, 49%)</td>
<td>↓ 32% (24, 39%)</td>
<td>ND</td>
</tr>
<tr>
<td>Fluticasone propionate aqueous nasal spray</td>
<td>200 mcg qd, 7 d</td>
<td>100 mg q12h, 7 d</td>
<td>18</td>
<td>↑ approximately 350-fold<sup>5</sup>
</td>
<td>↑ approximately 25-fold<sup>5</sup>
</td>
<td> </td>
</tr>
<tr>
<td>Indinavir<sup>1</sup>
<br/>Day 14 <br/>Day 15</td>
<td>400 q12h, 15 d</td>
<td>400 q12h, 15 d</td>
<td>10</td>
<td>
<br/>↑ 6% (-14, 29%)<br/>↓ 7% (-22, 28%)</td>
<td>
<br/>↓ 51% (40, 61%)<br/>↓ 62% (52, 70%)</td>
<td>↑ 4-fold (2.8, 6.8X)<br/>↑ 4-fold (2.5, 6.5X)</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>200 daily, 7 d</td>
<td>500 q12h, 10 d</td>
<td>12</td>
<td>↑ 3.4-fold (2.8, 4.3X)</td>
<td>↑ 55% (40, 72%)</td>
<td>ND</td>
</tr>
<tr>
<td>Meperidine <br/>
<br/>Normeperidine metabolite</td>
<td>50 oral single dose</td>
<td>500 q12h, 10 d</td>
<td>8<br/>
<br/>6</td>
<td>↓ 62% (59, 65%)<br/>
<br/>↑ 47% (-24, 345%)</td>
<td>↓ 59% (42, 72%)<br/>
<br/>↑ 87% (42, 147%)</td>
<td>ND<br/>
<br/>ND</td>
</tr>
<tr>
<td>Methadone<sup>2</sup>
</td>
<td>5, single dose</td>
<td>500 q12h, 15 d</td>
<td>11</td>
<td>↓ 36% (16, 52%)</td>
<td>↓ 38% (28, 46%)</td>
<td>ND</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>400, single dose</td>
<td>100 q12h, 16 d</td>
<td>10</td>
<td>↓ 16% (-30, 1%)</td>
<td>↓ 24% (-45, 4%)</td>
<td>↓ 1% (-30, 40%)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>10, single dose <br/>(days 0 and 7)</td>
<td>600 q12h<br/>(days 2 to 7)</td>
<td>12</td>
<td>↑ 150% (130-170%)<sup>7</sup>
</td>
<td>↑ 60% (40-70%)<sup>7</sup>
</td>
<td>ND</td>
</tr>
<tr>
<td>Rifabutin<br/>25-<content stylecode="italics">O</content>-desacetyl rifabutin metabolite</td>
<td>150 daily, 16 d</td>
<td>500 q12h, 10 d</td>
<td>5,<br/>
<br/>
<br/> 11*</td>
<td>↑ 4-fold (2.8, 6.1X)<br/>
<br/>↑ 38-fold (28, 56X)</td>
<td>↑ 2.5-fold (1.9, 3.4X)<br/>
<br/>↑ 16-fold (13, 20X)</td>
<td>↑ 6-fold (3.5, 18.3X)<br/>
<br/>↑ 181-fold (ND)</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>100, single dose</td>
<td>500 twice daily, 8 d</td>
<td>28</td>
<td>↑ 11-fold</td>
<td>↑ 4-fold</td>
<td>ND</td>
</tr>
<tr>
<td>Simeprevir</td>
<td>200 mg qd, 7 d</td>
<td>100 mg bid,15 d</td>
<td>12</td>
<td>↑ 618% (463%-815%)<sup>8</sup>
</td>
<td>↑370% (284%-476%)<sup>8</sup>
</td>
<td>↑1335% (929%-1901%)<sup>8</sup>
</td>
</tr>
<tr>
<td>Sulfamethoxazole<sup>3</sup>
</td>
<td>800, single dose</td>
<td>500 q12h, 12 d</td>
<td>15</td>
<td>↓ 20% (16, 23%)</td>
<td>↔</td>
<td>ND</td>
</tr>
<tr>
<td>Tadalafil</td>
<td>20 mg, single dose</td>
<td>200 mg q12h</td>
<td> </td>
<td>↑ 124%</td>
<td>↔</td>
<td>ND</td>
</tr>
<tr>
<td>Theophylline</td>
<td>3 mg/kg q8h, 15 d</td>
<td>500 q12h, 10 d</td>
<td>13, 11*</td>
<td>↓ 43% (42, 45%)</td>
<td>↓ 32% (29, 34%)</td>
<td>↓ 57% (55, 59%)</td>
</tr>
<tr>
<td>Trazodone</td>
<td>50 mg, single dose</td>
<td>200 mg q12h, 4 doses</td>
<td>10</td>
<td>↑ 2.4-fold</td>
<td>↑ 34%</td>
<td> </td>
</tr>
<tr>
<td>Trimethoprim<sup>3</sup>
</td>
<td>160, single dose</td>
<td>500 q12h, 12 d</td>
<td>15</td>
<td>↑ 20% (3, 43%)</td>
<td>↔</td>
<td>ND</td>
</tr>
<tr>
<td>Vardenafil</td>
<td>5 mg</td>
<td>600 q12h</td>
<td> </td>
<td>↑ 49-fold</td>
<td>↑ 13-fold</td>
<td>ND</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>400 q12h, 1 d; then 200 q12h, 8 d</td>
<td>400 q12h, 9 d</td>
<td> </td>
<td>↓ 82%</td>
<td>↓ 66%</td>
<td> </td>
</tr>
<tr>
<td> </td>
<td>400 q12h, 1 d; then 200 q12h, 8 d</td>
<td>100 q12h,  9 d</td>
<td> </td>
<td>↓ 39%</td>
<td>↓ 24%</td>
<td> </td>
</tr>
<tr>
<td>Warfarin<br/> S-Warfarin <br/>R-Warfarin</td>
<td>5, single dose</td>
<td>400 q12h, 12d</td>
<td>12</td>
<td>↑ 9% (-17, 44%)<sup>4</sup>
<br/>↓ 33% (-38, -27%)<sup>4</sup>
</td>
<td>↓ 9% (-16, -2%)<sup>4</sup>
<br/>↔</td>
<td>ND<br/>
<br/>ND</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>200 q8h, 4 d</td>
<td>300 q6h, 4 d</td>
<td>9</td>
<td>↓ 25% (15, 34%)</td>
<td>↓ 27% (4, 45%)</td>
<td>ND</td>
</tr>
<tr>
<td>1   Ritonavir and indinavir were co-administered for 15 days; Day 14 doses were administered after a 15%-fat breakfast (757 Kcal) and 9%-fat evening snack (236 Kcal), and Day 15 doses were administered after a 15%-fat breakfast (757 Kcal) and 32%-fat dinner (815 Kcal).  Indinavir C<sub>min</sub> was also increased 4-fold.  Effects were assessed relative to an indinavir 800 mg q8h regimen under fasting conditions.<br/>2   Effects were assessed on a dose-normalized comparison to a methadone 20 mg single dose.<br/>3   Sulfamethoxazole and trimethoprim taken as single combination tablet.<br/>4   90% CI presented for R- and S-warfarin AUC and C<sub>max</sub> ratios.<br/>5   This significant increase in plasma fluticasone propionate exposure resulted in a significant decrease (86%) in plasma cortisol AUC.<br/>6   For the reference arm: N=14 for C<sub>max</sub> and AUC<sub>(0-inf),</sub> and for the test arm: N=13 for C<sub>max</sub> and N=4 for AUC<sub>(0-inf)</sub>.<br/>7   90% CI presented for rivaroxaban<br/>8   90% CI presented for simeprevir (change in exposure presented as percentage increase)<br/>↑   Indicates increase.<br/>↓   Indicates decrease.<br/>↔   Indicates no change.<br/>*   Parallel group design; entries are subjects receiving combination and control regimens, respectively.</td>
</tr>
</tbody>
</table>